Pliant Therapeutics Stock Alpha and Beta Analysis
| PLRX Stock | USD 3.04 0.25 7.60% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Pliant Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Pliant Therapeutics over a specified time horizon. Remember, high Pliant Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Pliant Therapeutics' market risk premium analysis include:
Beta 1.63 | Alpha (1.69) | Risk 10.31 | Sharpe Ratio (0.15) | Expected Return (1.50) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Pliant |
Pliant Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Pliant Therapeutics market risk premium is the additional return an investor will receive from holding Pliant Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Pliant Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Pliant Therapeutics' performance over market.| α | -1.69 | β | 1.63 |
Pliant Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Pliant Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Pliant Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Pliant Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Pliant Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Pliant Therapeutics shares will generate the highest return on investment. By understating and applying Pliant Therapeutics stock market price indicators, traders can identify Pliant Therapeutics position entry and exit signals to maximize returns.
Pliant Therapeutics Return and Market Media
The median price of Pliant Therapeutics for the period between Mon, Nov 18, 2024 and Sun, Feb 16, 2025 is 12.98 with a coefficient of variation of 24.63. The daily time series for the period is distributed with a sample standard deviation of 2.98, arithmetic mean of 12.09, and mean deviation of 1.97. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Pliant Therapeutics Has Debt But No Earnings Should You Worry | 01/02/2025 |
2 | Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer | 01/22/2025 |
3 | Acquisition by Coulie Bernard of 325000 shares of Pliant Therapeutics at 11.14 subject to Rule 16b-3 | 01/23/2025 |
4 | Acquisition by Lefebvre Eric of 91300 shares of Pliant Therapeutics at 11.14 subject to Rule 16b-3 | 01/27/2025 |
5 | Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b3 Trialin Patients with Idiopathic Pulmonary Fibrosis | 02/07/2025 |
6 | This Illumina Analyst Turns Bearish Here Are Top 5 Downgrades For Monday | 02/10/2025 |
7 | How Is Pliant Therapeutics Navigating Market Challenges | 02/11/2025 |
8 | Pliant Therapeutics Announces Next Steps Following DSMB Recommendationon BEACON-IPF, a Phase 2b3 Trial in Patients with Idiopathic Pulmonary Fibrosis | 02/13/2025 |
About Pliant Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Pliant or other stocks. Alpha measures the amount that position in Pliant Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2025 (projected) | Payables Turnover | 2.33 | 2.2 | Days Of Inventory On Hand | 9.9E-5 | 1.18E-4 |
Pliant Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Pliant Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pliant Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Pliant Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Pliant Therapeutics. Please utilize our Beneish M Score to check the likelihood of Pliant Therapeutics' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Pliant Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.